source
- J&J's IBD combo fails Phase 2 studies, but will move into pivotal testingJohnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…Endpoints · 2mo ago↗ source
- Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't wantMadrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…Endpoints · 2mo ago↗ source
- Healthcare organizations are increasingly building their own AI toolsBig healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…